(Q58317803)

English

Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease

scientific article published in November 2014

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease (English)

0 references

0 references

corrigendum / erratum

Erratum to: Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease.

1 reference

10.1245/S10434-014-4303-4

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1245/S10434-014-4303-4

object named as

Saima Hassan

1

0 references

Andrea Baccarelli

object named as

Andrea Baccarelli

6

0 references

Danny Ghazarian

object named as

Danny Ghazarian

10

0 references

Suzanne Kamel-Reid

object named as

Suzanne Kamel-Reid

4

0 references

author name string

Teresa M. Petrella

2

0 references

Tong Zhang

3

0 references

Francesco Nordio

5

0 references

Shachar Sade

7

0 references

Karen Naert

8

0 references

Ayman Al Habeeb

9

0 references

Frances C. Wright

11

0 references

publication date

1 November 2014

0 references

Annals of Surgical Oncology

0 references

22

0 references

6

0 references

1950-1958

0 references

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Regional treatment strategies for in-transit melanoma metastasis

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Local and intralesional therapy of in-transit melanoma metastases

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Case of cutaneous malignant melanoma surviving 16 years with late recurrence

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

High response rate after intratumoral treatment with interleukin-2

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Intra-lesional interleukin-2 therapy for in transit melanoma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

KIT gene mutations and copy number in melanoma subtypes

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

An immune-active tumor microenvironment favors clinical response to ipilimumab

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Combination immunotherapy approaches

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Local therapy of cancer with free IL-2.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Intralesional immunotherapy for melanoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-4199-Z

21 January 2018

Identifiers

10.1245/S10434-014-4199-Z

0 references

Dimensions Publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58317803&oldid=2213805471"